[Comparison of the protective effects of roxatidine and misoprostol on diclofenac gastroduodenal pathology. An endoscopic, controlled study of volunteers].
For prophylaxis of gastroduodenal lesions induced by non-steroidal antirheumatic drugs (NSAID) acid-lowering as well as mucosa protective substances are used. Direct comparison of both therapeutic regimens are lacking. In randomized parallel studies the gastroduodenal tolerability of 100 mg diclofenac daily in slow-release form was evaluated in the presence and absence of 150 mg roxatidine (CAS 78273-80-0) daily as well as in the presence of 75 mg bid roxatidine or 200 micrograms bid misoprostol (CAS 59122-46-2). The drugs were taken over a period of 14 days. Endoscopic controls were performed at entry, as well as after 14 days of treatment. A quantitative damaging score was used. Study A: Both treatment groups (n = 20) had at entry comparable mucosal damages: placebo/diclofenac: 0.9 +/- 0.1 (+/- SEM), roxatidine/diclofenac: 0.9 +/- 0.1; after 14 days of treatment the score increased in the diclofenac/placebo group to 7.6 +/- 1.9 and, in the corresponding diclofenac/roxatidine group, only to 2.1 +/- 0.9. The difference between the two treatment groups after 14 days was significant (p < 0.05). Study B: Both treatment groups (n = 24) had comparable mucosal damages at entry: diclofenac/roxatidine: 0.9 +/- 0.1, diclofenac/misoprostol: 0.8 +/- 0.1. Following 14 days treatment with 100 mg diclofenac daily the damaging score in both group rose to comparable levels: roxatidine group 2.1 +/- 0.7 and misoprostol group 2.0 +/- 0.4 (n.s.). The data suggest that for prophylaxis of NSAID-induced gastroduodenal lesions substances with different mechanism of action can be used. The findings underline the complex way by which NSAID can damage the mucosa of the upper gastrointestinal tract.
Müller
P
P
Krankenhaus Salem, Heidelberg.
Jackisch
P
P
Simon
B
B
D000328:Adult; D000897:Anti-Ulcer Agents / Q000494:pharmacology*; D003692:Delayed-Action Preparations; D004008:Diclofenac / Q000009:adverse effects; D005744:Gastric Acid / Q000378:metabolism; D005773:Gastroscopy; D006635:Histamine H2 Antagonists / Q000494:pharmacology*; D006801:Humans; D016595:Misoprostol / Q000494:pharmacology*; D010880:Piperidines / Q000494:pharmacology*; D013276:Stomach Ulcer / Q000139:chemically induced / Q000473:pathology / Q000517:prevention & control*
D000897:Anti-Ulcer Agents; D003692:Delayed-Action Preparations; D006635:Histamine H2 Antagonists; D010880:Piperidines; D016595:Misoprostol; D004008:Diclofenac; C053742:roxatidine acetate
Vergleich der Schutzwirkung von Roxatidin und Misoprostol bei Diclofenac-Gastroduodenopathie. Endoskopisch kontrollierte Studien an freiwilligen Probanden.